Discover
TEVA
Teva Pharmaceutical Industries Limited
41.10
500 x 40.96
300 x 41.45
bid
ask
+
1.85
4.71%
400 @ 06:50 PM
41.22 +0.12 (0.30%)
| Ytd | 31.69% | |
| 1y | 105.09% |
40.12
day range
42.02
18.95
52 week range
41.10
| Open | 40.22 | Prev Close | 39.25 | Low | 40.12 | High | 42.02 | Mkt Cap | 47.93B |
| Vol | 14.82M | Avg Vol | 5.30M | EPS | 0.60 | P/E | 68.50 | Forward P/E | 13.31 |
| Beta | 0.82 | Short Ratio | 57.43 | Inst. Own | 24.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 11-28 | Earning | 11-03 | 50-d Avg | 37.51 | 200-d Avg | 33.86 | 1yr Est | 45.09 |
| Income Statement | |||
| Total Revenue | 4.14B | ||
| Revenues (USD) | 4.14B | ||
| Cost of Revenue | 1.99B | ||
| Gross Profit | 2.15B | ||
| Operating Expenses | 2.40B | ||
| Research and Development Expense | 970.00M | ||
| Selling, General and Administrative Expense | 1.03B | ||
| Operating Income | -250.00M | ||
| Interest Expense | 224.00M | ||
| Income Tax Expense | 121.00M | ||
| Net Income | -576.00M | ||
| Net Income Common Stock | -576.00M | ||
| Net Income Common Stock (USD) | -576.00M | ||
| Consolidated Income | -575.00M | ||
| Net Income to Non-Controlling Interests | 1000.00K | ||
| Earnings per Basic Share | -0.49 | ||
| Earnings per Basic Share (USD) | -0.49 | ||
| Earnings per Diluted Share | -0.49 | ||
| Earning Before Interest & Taxes (EBIT) | -231.00M | ||
| Earning Before Interest & Taxes (USD) | -231.00M | ||
| Weighted Average Shares | 1.17B | ||
| Weighted Average Shares Diluted | 1.17B | ||
| Balance Sheet | |||
| Cash and Equivalents | 3.66B | ||
| Cash and Equivalents (USD) | 3.66B | ||
| Trade and Non-Trade Receivables | 3.49B | ||
| Current Assets | 13.76B | ||
| Property, Plant & Equipment Net | 4.26B | ||
| Total Assets | 39.86B | ||
| Debt Current | 4.50B | ||
| Total Debt | 16.87B | ||
| Current Liabilities | 15.65B | ||
| Debt Non-Current | 12.37B | ||
| Total Liabilities | 32.10B | ||
| Accumulated Retained Earnings (Deficit) | -13.97B | ||
| Accumulated Other Comprehensive Income | -2.46B | ||
| Shareholders Equity | 7.75B | ||
| Shareholders Equity (USD) | 7.75B | ||
| Assets Non-Current | 26.10B | ||
| Total Debt (USD) | 16.87B | ||
| Goodwill and Intangible Assets | 19.29B | ||
| Inventory | 3.22B | ||
| Liabilities Non-Current | 16.45B | ||
| Trade and Non-Trade Payables | 2.72B | ||
| Tax Assets | 2.16B | ||
| Tax Liabilities | 4.08B | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 241.00M | ||
| Net Cash Flow from Financing | -1000.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -86.00M | ||
| Capital Expenditure | -104.00M | ||
| Net Cash Flow - Business Acquisitions and Disposals | -692.00M | ||
| Net Cash Flow from Investing | -491.00M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 310.00M | ||
| Net Cash Flow from Operations | 411.00M | ||
| Effect of Exchange Rate Changes on Cash | -5.00M | ||
| Share Based Compensation | 40.00M | ||